Gregory W. Daniel, PhD, MPH, RPh, directs the Duke-Margolis office in Washington, D.C. He leads the Center's pharmaceutical and medical device policy portfolio, which includes policy and data strategies for improving development and access to innovative pharmaceutical and medical device technologies. His expertise spans post-market evidence development to support increased value, improving regulatory science and drug development tools, optimizing biomedical innovation, and supporting drug and device payment reform.
Dr. Daniel is also a Senior Advisor to the Reagan-Udall Foundation for the FDA and Adjunct Associate Professor in the Division of Pharmaceutical Outcomes and Policy at the UNC Eshelman School of Pharmacy. Previously, he was Managing Director for Evidence Development & Biomedical Innovation in the Center for Health Policy and Fellow in Economic Studies at the Brookings Institution and Vice President, Government and Academic Research at HealthCore (subsidiary of Anthem, Inc). Dr. Daniel’s research expertise includes utilizing electronic health data in designing research in health outcomes and pharmacoeconomics, comparative effectiveness, and drug safety and pharmacoepidemiology.